New hope for hodgkin lymphoma patients: trial tests gentler treatment option
NCT ID NCT07234487
Summary
This study is comparing two different first-line treatment approaches for advanced Hodgkin lymphoma. One group receives a newer combination of immunotherapy (nivolumab) with chemotherapy (AVD), while the other receives standard chemotherapy regimens. The main goal is to see if the newer treatment is safer while still effectively controlling the cancer in 178 newly diagnosed patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Petersburg State Pavlov Medical University
RECRUITINGSaint Petersburg, Russia
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.